FR2502154A1 - Procede de preparation d'antigenes de l'hepatite virale nanb, et application a la realisation d'un reactif permettant le diagnostic et le pronostic des infections provoquees par les virus des hepatites virales - Google Patents
Procede de preparation d'antigenes de l'hepatite virale nanb, et application a la realisation d'un reactif permettant le diagnostic et le pronostic des infections provoquees par les virus des hepatites virales Download PDFInfo
- Publication number
- FR2502154A1 FR2502154A1 FR8106385A FR8106385A FR2502154A1 FR 2502154 A1 FR2502154 A1 FR 2502154A1 FR 8106385 A FR8106385 A FR 8106385A FR 8106385 A FR8106385 A FR 8106385A FR 2502154 A1 FR2502154 A1 FR 2502154A1
- Authority
- FR
- France
- Prior art keywords
- nanbe
- nanb
- nanbs
- nanbc
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 122
- 239000000427 antigen Substances 0.000 title claims abstract description 99
- 102000036639 antigens Human genes 0.000 title claims abstract description 98
- 108091007433 antigens Proteins 0.000 title claims abstract description 98
- 201000001862 viral hepatitis Diseases 0.000 title claims abstract description 18
- 206010019799 Hepatitis viral Diseases 0.000 title claims abstract description 16
- 239000003153 chemical reaction reagent Substances 0.000 title claims description 69
- 238000003745 diagnosis Methods 0.000 title claims description 13
- 208000015181 infectious disease Diseases 0.000 title description 34
- 238000004519 manufacturing process Methods 0.000 title description 9
- 238000004393 prognosis Methods 0.000 title description 3
- 210000002966 serum Anatomy 0.000 claims abstract description 84
- 238000000034 method Methods 0.000 claims abstract description 71
- 238000002360 preparation method Methods 0.000 claims abstract description 25
- 238000006243 chemical reaction Methods 0.000 claims abstract description 18
- 210000004185 liver Anatomy 0.000 claims abstract description 18
- 238000005199 ultracentrifugation Methods 0.000 claims abstract description 15
- 239000003599 detergent Substances 0.000 claims abstract description 14
- 238000005119 centrifugation Methods 0.000 claims abstract description 6
- 230000009471 action Effects 0.000 claims abstract description 5
- 239000000284 extract Substances 0.000 claims abstract description 4
- 239000012141 concentrate Substances 0.000 claims abstract description 3
- 238000012360 testing method Methods 0.000 claims description 73
- 239000000700 radioactive tracer Substances 0.000 claims description 46
- 238000001556 precipitation Methods 0.000 claims description 31
- 241001465754 Metazoa Species 0.000 claims description 28
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 27
- 108010074605 gamma-Globulins Proteins 0.000 claims description 22
- 239000007787 solid Substances 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 239000008188 pellet Substances 0.000 claims description 14
- 230000003612 virological effect Effects 0.000 claims description 14
- 239000002245 particle Substances 0.000 claims description 13
- 239000011780 sodium chloride Substances 0.000 claims description 13
- 238000001042 affinity chromatography Methods 0.000 claims description 11
- 230000002255 enzymatic effect Effects 0.000 claims description 10
- 208000002672 hepatitis B Diseases 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 7
- 230000001965 increasing effect Effects 0.000 claims description 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 5
- 238000010828 elution Methods 0.000 claims description 5
- 229960002897 heparin Drugs 0.000 claims description 5
- 229920000669 heparin Polymers 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 238000005194 fractionation Methods 0.000 claims description 3
- 238000011160 research Methods 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 238000011534 incubation Methods 0.000 abstract description 15
- 239000003795 chemical substances by application Substances 0.000 abstract description 11
- 238000011282 treatment Methods 0.000 abstract description 3
- 208000006454 hepatitis Diseases 0.000 description 53
- 231100000283 hepatitis Toxicity 0.000 description 46
- 210000004369 blood Anatomy 0.000 description 29
- 239000008280 blood Substances 0.000 description 29
- 238000000746 purification Methods 0.000 description 29
- 239000011324 bead Substances 0.000 description 28
- 239000000243 solution Substances 0.000 description 27
- 239000000872 buffer Substances 0.000 description 25
- 238000001962 electrophoresis Methods 0.000 description 23
- 238000001514 detection method Methods 0.000 description 21
- 230000000951 immunodiffusion Effects 0.000 description 21
- 241000283973 Oryctolagus cuniculus Species 0.000 description 18
- 238000010166 immunofluorescence Methods 0.000 description 15
- 230000009260 cross reactivity Effects 0.000 description 14
- 230000002458 infectious effect Effects 0.000 description 14
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 13
- 229930006000 Sucrose Natural products 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 239000005720 sucrose Substances 0.000 description 13
- 108090000340 Transaminases Proteins 0.000 description 12
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 12
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 12
- 235000011130 ammonium sulphate Nutrition 0.000 description 12
- 238000005406 washing Methods 0.000 description 12
- 229920002684 Sepharose Polymers 0.000 description 11
- 102000003929 Transaminases Human genes 0.000 description 11
- 239000000499 gel Substances 0.000 description 11
- 239000012071 phase Substances 0.000 description 11
- 230000002285 radioactive effect Effects 0.000 description 11
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 9
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 9
- 210000002381 plasma Anatomy 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 238000003127 radioimmunoassay Methods 0.000 description 8
- 239000004793 Polystyrene Substances 0.000 description 7
- 241000555745 Sciuridae Species 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 7
- 230000008878 coupling Effects 0.000 description 7
- 238000010168 coupling process Methods 0.000 description 7
- 238000005859 coupling reaction Methods 0.000 description 7
- 229920002223 polystyrene Polymers 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- 241000282577 Pan troglodytes Species 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 230000000890 antigenic effect Effects 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 239000007822 coupling agent Substances 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 229940072221 immunoglobulins Drugs 0.000 description 6
- 102000013415 peroxidase activity proteins Human genes 0.000 description 6
- 108040007629 peroxidase activity proteins Proteins 0.000 description 6
- 230000001376 precipitating effect Effects 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 5
- 206010019791 Hepatitis post transfusion Diseases 0.000 description 5
- 241000282579 Pan Species 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- 210000002845 virion Anatomy 0.000 description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- 206010008909 Chronic Hepatitis Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000700721 Hepatitis B virus Species 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 4
- 239000001166 ammonium sulphate Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 238000001493 electron microscopy Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 239000011630 iodine Substances 0.000 description 4
- 230000000405 serological effect Effects 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 108010082126 Alanine transaminase Proteins 0.000 description 3
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 3
- -1 C1Na) are removed Chemical class 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- 206010058874 Viraemia Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000004931 aggregating effect Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000000234 capsid Anatomy 0.000 description 3
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000037029 cross reaction Effects 0.000 description 3
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- VLEIUWBSEKKKFX-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O VLEIUWBSEKKKFX-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 2
- 241000283923 Marmota monax Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 208000037084 Viral Human Hepatitis Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000002532 anti-gammaglobulin Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 231100000749 chronicity Toxicity 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 210000004201 immune sera Anatomy 0.000 description 2
- 229940042743 immune sera Drugs 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000003547 immunosorbent Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 230000002747 voluntary effect Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- 241001556567 Acanthamoeba polyphaga mimivirus Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- IYLLULUTZPKQBW-UHFFFAOYSA-N Acrinol Chemical compound CC(O)C(O)=O.C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 IYLLULUTZPKQBW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010056522 Hepatic infection Diseases 0.000 description 1
- 206010019786 Hepatitis non-A non-B Diseases 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229910000694 Nambé Inorganic materials 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 241001637516 Polygonia c-album Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 208000035999 Recurrence Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000002298 density-gradient ultracentrifugation Methods 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 125000005442 diisocyanate group Chemical group 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- YUPQOCKHBKYZMN-UHFFFAOYSA-N ethylaminomethanetriol Chemical compound CCNC(O)(O)O YUPQOCKHBKYZMN-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000727 fraction Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- JMANVNJQNLATNU-UHFFFAOYSA-N glycolonitrile Natural products N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- XMBWDFGMSWQBCA-RNFDNDRNSA-M iodine-131(1-) Chemical compound [131I-] XMBWDFGMSWQBCA-RNFDNDRNSA-M 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000004313 potentiometry Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000011403 purification operation Methods 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 238000003156 radioimmunoprecipitation Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- DVKJHBMWWAPEIU-UHFFFAOYSA-N toluene 2,4-diisocyanate Chemical compound CC1=CC=C(N=C=O)C=C1N=C=O DVKJHBMWWAPEIU-UHFFFAOYSA-N 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8106385A FR2502154A1 (fr) | 1981-03-30 | 1981-03-30 | Procede de preparation d'antigenes de l'hepatite virale nanb, et application a la realisation d'un reactif permettant le diagnostic et le pronostic des infections provoquees par les virus des hepatites virales |
| AT82900965T ATE15605T1 (de) | 1981-03-30 | 1982-03-30 | Verfahren zur herstellung von antigenen der nanb- viralen hepatitis und ihre verwendung zur herstellung eines reagenzes fuer die diagnose und prognose von durch ein virus der viralen hepatiten verursachten infektionen. |
| PCT/FR1982/000060 WO1982003330A1 (en) | 1981-03-30 | 1982-03-30 | Method for the preparation of antigens of the viral hepatitis nanb,and application to the preparation of a reaction agent allowing the diagnostic and pronostic of infections caused by the viruses of viral hepatitis |
| DE8282900965T DE3266294D1 (en) | 1981-03-30 | 1982-03-30 | Method for the preparation of antigens of the viral hepatitis nanb, and application to the preparation of a reaction agent allowing the diagnosis and prognosis of infections caused by the viruses of viral hepatitis |
| EP82900965A EP0074986B1 (fr) | 1981-03-30 | 1982-03-30 | Procede de preparation d'antigenes de l'hepatite virale nanb, et application a la realisation d'un reactif permettant le diagnostic et le pronostic des infections provoquees par les virus des hepatites virales |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8106385A FR2502154A1 (fr) | 1981-03-30 | 1981-03-30 | Procede de preparation d'antigenes de l'hepatite virale nanb, et application a la realisation d'un reactif permettant le diagnostic et le pronostic des infections provoquees par les virus des hepatites virales |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2502154A1 true FR2502154A1 (fr) | 1982-09-24 |
| FR2502154B1 FR2502154B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1984-01-27 |
Family
ID=9256801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8106385A Granted FR2502154A1 (fr) | 1981-03-30 | 1981-03-30 | Procede de preparation d'antigenes de l'hepatite virale nanb, et application a la realisation d'un reactif permettant le diagnostic et le pronostic des infections provoquees par les virus des hepatites virales |
Country Status (4)
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0242300A1 (fr) * | 1986-04-16 | 1987-10-21 | Institut Pasteur | Nouveau réactif pour la détection d'hépatites virales non-a non-b et procédé de diagnostic de telles hépatites par voie immunoenzymatique |
| WO2001009609A3 (en) * | 1999-07-28 | 2003-01-09 | Chiron Corp | Hepatitis c viral antigen immunoassay detection systems |
| US6815160B1 (en) | 1999-07-28 | 2004-11-09 | Chiron Corporation | Hepatitis C viral antigen immunoassay detection systems |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4542016A (en) * | 1981-03-27 | 1985-09-17 | Institut Merieux | Non-a non-b hepatitis surface antigen useful for the preparation of vaccines and methods of use |
| JPS57198867A (en) * | 1981-06-02 | 1982-12-06 | Eisai Co Ltd | Non-a, non-b hepatitis related antigen and diagnostic therefor |
| JPS58753A (ja) * | 1981-06-25 | 1983-01-05 | Eisai Co Ltd | 非ａ非ｂ型肝炎関連抗体および検出試薬 |
| JPS58183629A (ja) * | 1982-04-21 | 1983-10-26 | Eisai Co Ltd | 非ａ非ｂ型肝炎関連モノクロナ−ル抗体および診断薬 |
| EP0119259A4 (en) * | 1982-09-16 | 1988-08-04 | Gen Hospital Corp | Non a, non b hepatitis virus, methods of identification, purification, characterization, diagnosis and immunization. |
| DE3316464A1 (de) * | 1983-05-05 | 1984-11-08 | Heinrich Prof Dr Med Liehr | Virusantigen, verfahren zu seiner gewinnung und anwendung in diagnose und therapie (impfstoff) |
| US4673634A (en) * | 1985-03-08 | 1987-06-16 | The United States Of America As Represented By The Department Of Health And Human Services | Purified antigen from non-A, non-B hepatitis causing factor |
| FR2606515B1 (fr) * | 1986-11-07 | 1992-02-21 | Pasteur Institut | Procede pour l'isolement d'un nouvel agent viral et de l'antigene qui lui est associe, agent viral et antigene obtenus par ce procede et procede de detection dudit antigene a l'aide d'un reactif immunologique approprie |
| NZ222465A (en) * | 1986-11-07 | 1992-11-25 | Pasteur Institut | Nanb (non a, non b hepatitis viral) antigen |
| FR2609807B2 (fr) * | 1987-02-11 | 1992-05-29 | Pasteur Institut | Reactifs immunologiques pour la detection de l'hepatite virale nanb, leurs procedes de preparation et leurs applications dans des procedes de detection de l'hepatite virale nanb et en tant qu'agents therapeutiques |
| DE3744242A1 (de) * | 1987-02-20 | 1989-07-06 | Seelig Renate | Virusantigen, verfahren zu seiner gewinnung und anwendung in diagnose und therapie (impfstoff) |
| YU48038B (sh) * | 1987-11-18 | 1996-10-18 | Chiron Corp. | Postupak za dijagnostiku ne-a, ne-v hepatitisa |
| US5350671A (en) * | 1987-11-18 | 1994-09-27 | Chiron Corporation | HCV immunoassays employing C domain antigens |
| US6861212B1 (en) | 1987-11-18 | 2005-03-01 | Chiron Corporation | NANBV diagnostics and vaccines |
| US6171782B1 (en) | 1987-11-18 | 2001-01-09 | Chiron Corporation | Antibody compositions to HCV and uses thereof |
| US5712088A (en) * | 1987-11-18 | 1998-01-27 | Chiron Corporation | Methods for detecting Hepatitis C virus using polynucleotides specific for same |
| US5714596A (en) * | 1987-11-18 | 1998-02-03 | Chiron Corporation | NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus |
| US5698390A (en) * | 1987-11-18 | 1997-12-16 | Chiron Corporation | Hepatitis C immunoassays |
| US6027729A (en) * | 1989-04-20 | 2000-02-22 | Chiron Corporation | NANBV Diagnostics and vaccines |
| DE102007046271A1 (de) | 2007-09-20 | 2009-04-02 | Sitech Sitztechnik Gmbh | Anordnung eines Gurtretraktors an einem Gurtintegralsitz |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1105178A (en) * | 1965-11-17 | 1968-03-06 | Andreas Lembke | Improvements in or relating to antigens suitable for the diagnosis of hepatitis |
| WO1980002598A1 (en) * | 1979-05-21 | 1980-11-27 | Us Commerce | Detection of non-a,non-b hepatitis associated antigen |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57198867A (en) * | 1981-06-02 | 1982-12-06 | Eisai Co Ltd | Non-a, non-b hepatitis related antigen and diagnostic therefor |
| JPS58753A (ja) * | 1981-06-25 | 1983-01-05 | Eisai Co Ltd | 非ａ非ｂ型肝炎関連抗体および検出試薬 |
-
1981
- 1981-03-30 FR FR8106385A patent/FR2502154A1/fr active Granted
-
1982
- 1982-03-30 DE DE8282900965T patent/DE3266294D1/de not_active Expired
- 1982-03-30 WO PCT/FR1982/000060 patent/WO1982003330A1/en active IP Right Grant
- 1982-03-30 EP EP82900965A patent/EP0074986B1/fr not_active Expired
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1105178A (en) * | 1965-11-17 | 1968-03-06 | Andreas Lembke | Improvements in or relating to antigens suitable for the diagnosis of hepatitis |
| WO1980002598A1 (en) * | 1979-05-21 | 1980-11-27 | Us Commerce | Detection of non-a,non-b hepatitis associated antigen |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0242300A1 (fr) * | 1986-04-16 | 1987-10-21 | Institut Pasteur | Nouveau réactif pour la détection d'hépatites virales non-a non-b et procédé de diagnostic de telles hépatites par voie immunoenzymatique |
| FR2597606A1 (fr) * | 1986-04-16 | 1987-10-23 | Pasteur Institut | Nouveau reactif pour la detection d'hepatites virales non a non b et procede de diagnostic de telles hepatites par voie immunoenzymatique |
| WO2001009609A3 (en) * | 1999-07-28 | 2003-01-09 | Chiron Corp | Hepatitis c viral antigen immunoassay detection systems |
| US6815160B1 (en) | 1999-07-28 | 2004-11-09 | Chiron Corporation | Hepatitis C viral antigen immunoassay detection systems |
| US7108967B2 (en) | 1999-07-28 | 2006-09-19 | Novartis Vaccines And Diagnostics, Inc. | Hepatitis C viral antigen immunoassay detection systems |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1982003330A1 (en) | 1982-10-14 |
| FR2502154B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1984-01-27 |
| EP0074986B1 (fr) | 1985-09-18 |
| EP0074986A1 (fr) | 1983-03-30 |
| DE3266294D1 (en) | 1985-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0074986B1 (fr) | Procede de preparation d'antigenes de l'hepatite virale nanb, et application a la realisation d'un reactif permettant le diagnostic et le pronostic des infections provoquees par les virus des hepatites virales | |
| Wigzell et al. | Separation of cells according to surface antigens by the use of antibody‐coated columns. Fractionation of cells carrying immunoglobulins and blood group antigen | |
| KR900008007B1 (ko) | 프리(pre)-S 유전자 코우드로 된 펩티드 B형 간염 면역원, 왁찐, 진단법 및 합성지질소낭 담체 | |
| US5086002A (en) | Erythrocyte agglutination assay | |
| JPH01501205A (ja) | 非ａ非ｂ型肝炎由来の新規ウイルス因子及びそれに結合した抗原の単離方法、この方法で得られたウイルス因子及び抗原、この抗原の検出方法並びに非ａ非ｂ型ウイルス性肝炎検出用免疫試薬、その製造法及び用途 | |
| EP0138667A2 (fr) | Méthode pour le diagnostic de lymphadénopathie et du syndrome d'immuno-dépression acquise | |
| US3994870A (en) | Purification of hepatitis B surface antigen | |
| DE60113139T2 (de) | Hcv mosaik antigen zusammensetzung | |
| Madaliński et al. | HBsAg immune complexes in the course of infection with hepatitis B virus | |
| EP0242300B1 (fr) | Nouveau réactif pour la détection d'hépatites virales non-a non-b et procédé de diagnostic de telles hépatites par voie immunoenzymatique | |
| Gomara et al. | Use of linear and multiple antigenic peptides in the immunodiagnosis of acute hepatitis A virus infection | |
| CA1090701A (fr) | Medicament permettant de traiter les infections aigues ou chroniques dues au virus de l'hepatite b | |
| JPH0327297A (ja) | Ｂ型肝炎ウイルスエンベロープＰｒｅＳ１およびＰｒｅＳ２タンパク質に特異的なモノクローナル抗体 | |
| EP0569309B1 (fr) | Polypeptides de synthèse appartenant au virus de l'hépatite C (VHC) et utilisables notamment pour détecter ce dernier | |
| EP0068465B1 (en) | Non-a, non-b hepatitis-associated antibody conjugate, the use thereof and detection reagent | |
| CN112903996A (zh) | 一种nCoV-N蛋白检测试剂盒以及nCoV-N蛋白检测方法 | |
| FR2767324A1 (fr) | Utilisation de proteines d'enveloppe recombinantes pour le diagnostic du virus de la dengue | |
| WO1995006719A1 (fr) | Methode d'immunodosage specifique de la glutathion peroxydase plasmatique humaine | |
| FR2555755A1 (fr) | Procede de dosage des immunoglobulines humaines qui sont specifiques d'antigenes cancereux humains et application de ce procede dans le serodiagnostic de maladies tumorales primitives | |
| EP0308242B1 (en) | Agglutination assay | |
| JP2004294157A (ja) | 金コロイドと抗体の結合体を製造する方法 | |
| Swartzwelder et al. | Heart-reactive antibodies in rabbit anti-Streptococcus mutans sera fail to cross-react with Streptococcus mutans. | |
| CA1197187A (fr) | Procede et chaine reactionnelle pour le diagnostic de la leucose bovine enzootique | |
| FR2606515A1 (fr) | Procede pour l'isolement d'un nouvel agent viral et de l'antigene qui lui est associe, agent viral et antigene obtenus par ce procede et procede de detection dudit antigene a l'aide d'un reactif immunologique approprie | |
| WO1991005059A1 (fr) | Anticorps monoclonal reconnaissant une region pre-s1 de la grande proteine d'enveloppe du virus de l'hepatite b |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |